Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
NCT06201416
This study is recruiting at 9 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
This study will test the safety and effects of SBT777101 when given as a single dose to subjects with rheumatoid arthritis. It is the first study of this treatment being done in humans. Increasing dose levels will be given after the safety at lower dose levels is shown. Following completion of the initial single ascending dose cohorts, the study may evaluate alternative administration regimens of SBT777101, including split-dose administration.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Rheumatoid Arthritis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Sonoma Biotherapeutics, Inc.
- Last updated on ClinicalTrials.gov
- June 30, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Mayo Clinic · Scottsdale, AZ
California · 2
- UCSF Medical Center · San Francisco, CA
- Stanford Medical Center · Stanford, CA
Colorado · 1
- University of Colorado · Aurora, CO
Illinois · 1
- Northwestern University · Chicago, IL
Massachusetts · 3
- Brigham and Women's Hospital · Boston, MA
- Massachusetts General Hospital · Boston, MA
- Tufts University · Boston, MA
Oregon · 1
- Oregon Health Sciences University · Portland, OR
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.